RobertMDS Patient

The Right Expression Can Change a Life

When genes are expressed - turned on, off, up or down - at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By creating medicines to control the expression of genes that have gone awry in disease, we aim to make a profound difference in the lives of patients and their families. We are advancing a growing pipeline of investigational medicines that control the expression of disease-driving genes with the aim of providing a profound and durable benefit for patients with diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer, including immuno-oncology, as well as autoimmune and genetic diseases.

Program Indication Preclinical Early Clinical Mid-Stage Clinical Pivotal Commercial Rights
SY-1425 (RARα agonist)
SY-1425 (RARα agonist)
Relapsed or refractory AML
Preclinical Phase complete
Early Clinical Phase complete
Mid-Stage Clinical Phase in progress
Pivotal Phase not started
North America & Europe
North America & Europe
SY-1425 (RARα agonist)
Newly diagnosed, unfit AML (monotherapy and combination)
Preclinical Phase complete
Early Clinical Phase complete
Mid-Stage Clinical Phase in progress
Pivotal Phase not started
North America & Europe
SY-1425 (RARα agonist)
Relapsed or refractory higher-risk MDS
Preclinical Phase complete
Early Clinical Phase complete
Mid-Stage Clinical Phase in progress
Pivotal Phase not started
North America & Europe
SY-1425 (RARα agonist)
Lower-risk transfusion-dependent MDS
Preclinical Phase complete
Early Clinical Phase complete
Mid-Stage Clinical Phase in progress
Pivotal Phase not started
North America & Europe
SY-1425 (RARα agonist)
Breast cancer
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
North America & Europe
SY-1365 (CDK7 inhibitor)
SY-1365 (CDK7 inhibitor)
Solid Tumors (TNBC, Ovarian, SCLC)
Preclinical Phase complete
Early Clinical Phase in progress
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Worldwide
Worldwide
SY-1365 (CDK7 inhibitor)
Acute Leukemia (AML and ALL)
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Worldwide
Oral CDK7 Inhibitor
Oral CDK7 Inhibitor
Cancer
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Worldwide
Worldwide
Oral CDK12/13 Inhibitor
Oral CDK12/13 Inhibitor
Cancer
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Worldwide
Worldwide
Program 5
Program 5
Cancer / Immuno-oncology
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Worldwide
Worldwide
Program 6
Program 6
Cancer
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Worldwide
Worldwide

Interested in Participating in a Clinical Trial?

If you’re interested in participating in a clinical trial, check to see if a trial is open near your area and if you meet the requirements to participate.

Learn More

Partnership Opportunities

We are actively seeking partnerships to maximize the value of our programs and extend the potential of our gene control platform across multiple therapeutic areas and diseases.

View Our Partnership Focus

Our Publications and Abstracts

Learn more about the science and data behind our platform and our programs.

Read Publications and Abstracts